Imjudo (Tremelimumab)

• Imjudo is employed in the management of urothelial carcinoma, an advanced bladder cancer, as part of an immune checkpoint inhibition strategy.
• Locally advanced urothelial carcinoma: used with durvalumab to boost immune activation and improve surgical outcomes.
• Metastatic urothelial carcinoma: combined therapy aims to extend survival and delay disease progression in patients with disseminated disease.
• Bladder cancer recurrence prevention: in selected patients, the regimen may reduce the risk of tumor recurrence after initial treatment.
• High‑risk urothelial carcinoma post‑cystectomy: administered as adjuvant therapy to lower the chance of relapse.

• Tremelimumab is a fully human IgG2 monoclonal antibody that binds to the cytotoxic T‑lymphocyte‑associated protein 4 (CTLA‑4) receptor on activated T cells. By blocking CTLA‑4 interaction with its ligands CD80 and CD86, the drug prevents inhibitory signaling, thereby sustaining T‑cell proliferation and cytokine production. This enhanced immune activation promotes recognition and destruction of tumor cells, forming the basis of its activity as an immune checkpoint inhibitor in cancer therapy. The blockade results in a broader repertoire of tumor‑specific T‑cell responses.

Tremelimumab may cause a range of immune‑related adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Skin rash: erythematous or maculopapular eruptions.
• Diarrhea: mild to moderate loose stools.
• Nausea: occasional queasiness or upset stomach.

Serious or Rare Side Effects

• Colitis: severe inflammation of the colon that may lead to perforation.
• Hepatitis: elevated liver enzymes indicating liver inflammation.
• Endocrinopathies: dysfunction of thyroid, pituitary or adrenal glands requiring hormone replacement.

Prior to initiating Tremelimumab therapy, clinicians should evaluate patients for factors that may increase the risk of adverse events.

• Monitor immune‑related adverse events: assess organ function regularly throughout treatment.
• Screen for active autoimmune disease: avoid use in patients with uncontrolled autoimmune disorders.
• Evaluate hepatic function: baseline liver enzymes should be measured and monitored.
• Avoid live vaccines during therapy: immunosuppression may cause severe infection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tremelimumab can interact with other agents that modify immune function or affect safety profiles.

Major Interactions (Avoid)

• Concurrent use with other immune checkpoint inhibitors: heightened risk of severe immune‑mediated toxicity.
• High‑dose systemic steroids: may diminish therapeutic efficacy of Tremelimumab.
• Live attenuated vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Immunosuppressive chemotherapy: may alter immune activation and require dose adjustments.
• Anticoagulants: monitor for bleeding complications during infusion reactions.
• Drugs affecting cytokine release: observe for additive inflammatory responses.